IBX
Tradr 2X Long IBM Daily ETF
$17.23
$-0.10 (-0.58%)
Real-time · Sep 3, 2026 4:00 AM ET
Key Statistics
Net Assets (AUM)
$39.60M
Expense Ratio
See prospectus
Previous Close
$17.33
Day Range
- – -
52-Week Range
$12.91 – $42.33
Volume
2
Avg Vol (50D)
-
Beta
-16.91
Historical Performance
1M
+4.84%
3M
-51.32%
6M
—
YTD
—
1Y
-26.40%
3Y
—
5Y
—
Total return including reinvested distributions, from adjusted closing prices.
Price History
Price history is being compiled for this fund.
Top Holdings
CFD INTL BUSINESS MACHINES CORP
-1.74%
Top 1 holdings as of Mar 31, 2026 · source: SEC N-PORT. Full holdings & prospectus →
IBX News
- Imagion Biosystems Seeks ASX Listing for 7.5 Million Lead Manager Options Issued to CPS Capital Group
- Imagion Biosystems Files Section 708A Notice for 40.2 Million Listed Options Issued in Placement
- Imagion Biosystems Seeks ASX Quotation for 32.7 Million Options Expiring December 2027
- Imagion Biosystems Finalizes CRO Agreements and Completes MagSense Manufacturing for Phase 1b/2 Breast Cancer Clinical Trial
- Imagion Biosystems Seeks ASX Quotation for 152.5 Million Shares and Options from June 2026 Capital Raise
- Imagion Biosystems Announces Issuance of 152.5 Million Shares and 156 Million Options Under Section 708A Cleansing Notice
- Imagion Biosystems Seeks ASX Quotation for 108.5 Million Shares from June Placement Tranche 2
- Imagion Biosystems Secures Unanimous Shareholder Approval on All Nine Resolutions at August 2026 General Meeting
- Which ASX Healthcare Stocks Advanced Through Clinical and Regulatory Milestones?
- Imagion Biosystems to Issue 17.9 Million Shares on Loan Conversion with Shareholder Approval
- Imagion Biosystems Obtains US$150,000 Non-Dilutive Loan from Executive Chairman Robert Proulx
- Imagion Biosystems (IBX) Announces Virtual General Meeting on August 10, 2026, Featuring Key Shareholder Resolutions
Data for IBX is aggregated from third-party providers (Tiingo, Nasdaq, Finnhub) and SEC filings, may be delayed at least 20 minutes, and may be incomplete or contain errors. Nothing here is investment advice. Verify with the official prospectus before investing.